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The cerebral cortex is the most complex structure of our brain. During 
evolution, the relative size of the cortex has increased considerably among 
higher mammals and new cortical areas involved in higher evolved functions 
have emerged. Here, we describe an intrinsic pathway of corticogenesis from 
human embryonic (ESC) and induced pluripotent (iPSC) stem cells leading to 
the sequential generation of first forebrain progenitors and later pyramidal 
neurons of all six layers identities in a time-dependent fashion, highly 
reminiscent of the in vivo situation. Moreover, the hESC-derived neurons 
followed a neuronal maturation program where late born neurons of about two 
months in vitro expressed a variety of genes involved in cortical neuronal 
function and where the majority of the neuronal population was characterized 
by the presence of synapses in vitro. Following transplantation into mouse 
neonatal brain, human ESC-derived cortical neurons integrated robustly into 
the host brain and established specific axonal projections and dendritic 
patterns corresponding to native cortical neurons. The differentiation and 
connectivity of the transplanted human cortical neurons complexified 
progressively over several months in vivo, culminating in the establishment of 
functional synapses with the host circuitry. Importantly, our data not only 
demonstrate in vitro, as well as in vivo, the cortical identity of the neurons 
differentiated from human ESC, but also provide a faithful model of human 
cortical development, from early neurogenesis to neuronal maturation and 
generation of neuronal circuits, with implications for the modelling and 
treatment of neuropsychiatric and neurological diseases and brain repair. 
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XIVth BELACT Meeting 
Advanced models of (stem) cells in toxicology, pharmacology, safety 
assessment, and cell therapy. 
Friday December the 14th, 2012 
ULB - Erasme campus  - Musée de la Médecine 
 
9:00 – 9.45 : Welcome & registration - Coffee 
Morning session – Advanced (stem) cell models in cell  
• 9:45–10:00 Martine Raes (BELACT Chairwoman) and Pierre Vanderhaeghen (ULB, 
Chairman of the morning session) – Introduction  
• 10:00-10:40 Cedric Blanpain  (ULB) “Multipotent and pluripotent cardiovascular      
progenitors during development stem cells differentiation " 
• 10:40-11:20 Sabine Costagliola (ULB) "Functional thyroid 
tissue derived from pluripotent stem cells"  
        11:20-11:40   Short coffee break  
• 11:40-12:00  Mustapha Najimi (UCL) “Adult human liver mesenchymal stem/progenitor 
cells participate to mouse liver regeneration after hepatectomy” 
•     12:00-12:20 Ira Espuny Camacho (ULB) “Corticogenesis from human pluripotent stem 
cells leads to the generation of pyramidal neurons with diverse and complex 
hodological properties” 
• 12:20-12:40   Laurence Borgs (ULG) “Novel strategy to differentiate human induced 
pluripotent stem cells into dopaminergic neurons” 
12:40 -14:00  Poster Session & Exhibition - Sandwiches 
Afternoon session  – Advanced (stem) cell models in cell toxicology and safety 
assessment (chairman Stefanos Grammatikos) 
• 14:00-14:35  Sonja Beken (FAGG-AFMPS)  “Overview on the regulatory acceptance 
and use of in vitro models for non-clinical testing of human medicinal products”. 
• 14:35–14:55 Jean-Pascal Piret (Univ. Namur)  “Use of in vitro models for the 
evaluation of potential toxic effects of engineered nanoparticles” 
• 14:55-15:15 Christoph Giese (ProBiogen, Berlin) A human lymphoid organ model 
(HuALN) for predictive testing of immunogenicity, immunotoxicity and immune 
functions in vitro” 
•  15:15-15:35  Short coffee break 
• 15:35-16:15 Franck Atienzar (UCB) "Evaluation of different cellular models and 
endpoints for the detection of Human Hepatotoxic Drugs” 
•    16:15-16:30 Gisèle Deblandre (MaSThercell) “How to meet the challenges associated 
with the   development of cell-based medicinal products” 
•  16:30:16:40  Conclusion - Stefanos Grammatikos (ESACT) Lille 2013 
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•         16:45-16:50  John Wérenne (ULB) - Conclusion 
 
 
BELACT REPLY FORM 
(KINDLY RETURN THIS FORM BY MAIL ASAP) 
 
 
TO :   I. Knott / N. Hantson  
  at GlaxoSmithKline Vaccines EMAIL :isabelle.knott@gsk.com 
   cc Biocelan@ulb.ac.be 
 
FROM :  
NAME : ............................................................................................. 
ADDRESS :....................................................................................... 
.......................................................................................................... 
TEL : ................................................................................................. 
FAX : ................................................................................................. 
E-MAIL : ............................................................................................ 
 
 
§ The BELACT Committee welcomes in particular graduate or post-graduate students 
and the program of the day can be included in 2nd or 3rd cycle courses.  
 




§ I will participate to the XIVth BELACT meeting.           
(payment 10 EUROs student – 20 EUROs non-student at the registration desk     




Please note also that prize(s) for the best poster(s) presented will be offered ; this year 
a special bursary (registration, hotel and travel expenses ) is offered by ESACT to 
attend the Lille ESACT meeting ( June 23-26). 
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